Peter McLaughlin

26.0k total citations · 4 hit papers
404 papers, 18.0k citations indexed

About

Peter McLaughlin is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Peter McLaughlin has authored 404 papers receiving a total of 18.0k indexed citations (citations by other indexed papers that have themselves been cited), including 266 papers in Pathology and Forensic Medicine, 150 papers in Oncology and 117 papers in Genetics. Recurrent topics in Peter McLaughlin's work include Lymphoma Diagnosis and Treatment (258 papers), Chronic Lymphocytic Leukemia Research (113 papers) and Viral-associated cancers and disorders (89 papers). Peter McLaughlin is often cited by papers focused on Lymphoma Diagnosis and Treatment (258 papers), Chronic Lymphocytic Leukemia Research (113 papers) and Viral-associated cancers and disorders (89 papers). Peter McLaughlin collaborates with scholars based in United States, Germany and Canada. Peter McLaughlin's co-authors include Fernando Cabanillas, Fredrick B. Hagemeister, Jorge Romaguera, Maria Alma Rodriguez, Anas Younes, F Swan, Barbara Pro, A.J. Grillo-López, Luis Fayad and Christine A. White and has published in prestigious journals such as Science, JAMA and Journal of Clinical Investigation.

In The Last Decade

Peter McLaughlin

400 papers receiving 17.3k citations

Hit Papers

Rituximab chimeric anti-C... 1988 2026 2000 2013 1998 2000 2009 1988 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    1998 2.2k citations Peter McLaughlin, A.J. Grillo-López et al. Journal of Clinical Oncology profile →
  2. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
    2000 523 citations Christine A. White, Peter McLaughlin et al. Journal of Clinical Oncology profile →
  3. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
    2009 506 citations Massimo Federico, Monica Bellei et al. Journal of Clinical Oncology profile →
  4. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
    1988 487 citations Fernando Cabanillas, Peter McLaughlin et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peter McLaughlin 11.2k 7.5k 5.6k 2.7k 2.4k 404 18.0k
Steven T. Rosen 6.5k 0.6× 5.7k 0.8× 1.9k 0.3× 3.3k 1.2× 1.6k 0.7× 423 15.9k
Shigeo Nakamura 9.5k 0.9× 7.9k 1.0× 2.6k 0.5× 4.0k 1.5× 2.9k 1.2× 508 18.5k
Reiner Siebert 10.7k 1.0× 6.8k 0.9× 5.3k 0.9× 3.6k 1.3× 2.6k 1.1× 332 20.1k
Peter de Nully Brown 3.2k 0.3× 6.3k 0.8× 1.8k 0.3× 1.2k 0.4× 947 0.4× 344 15.4k
Peter C. Nowell̀ 4.0k 0.4× 6.8k 0.9× 5.0k 0.9× 5.3k 2.0× 651 0.3× 294 28.9k
Jennifer R. Brown 6.5k 0.6× 3.6k 0.5× 8.3k 1.5× 3.6k 1.3× 331 0.1× 451 14.5k
Albert de la Chapelle 16.2k 1.4× 12.3k 1.6× 2.2k 0.4× 2.2k 0.8× 654 0.3× 546 43.1k
Charis Eng 5.7k 0.5× 9.8k 1.3× 2.5k 0.4× 2.4k 0.9× 2.3k 1.0× 647 44.8k
Anke van den Berg 4.3k 0.4× 5.6k 0.7× 1.4k 0.3× 2.9k 1.1× 1.2k 0.5× 364 19.3k
Neil E. Kay 8.4k 0.8× 3.0k 0.4× 11.3k 2.0× 6.9k 2.6× 221 0.1× 493 17.3k

Countries citing papers authored by Peter McLaughlin

Since Specialization
Citations

This map shows the geographic impact of Peter McLaughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter McLaughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter McLaughlin more than expected).

Fields of papers citing papers by Peter McLaughlin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter McLaughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter McLaughlin. The network helps show where Peter McLaughlin may publish in the future.

Co-authorship network of co-authors of Peter McLaughlin

This figure shows the co-authorship network connecting the top 25 collaborators of Peter McLaughlin. A scholar is included among the top collaborators of Peter McLaughlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter McLaughlin. Peter McLaughlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bennett, Elizabeth & Peter McLaughlin. (2023). Neuroscience explanations really do satisfy: A systematic review and meta-analysis of the seductive allure of neuroscience. Public Understanding of Science. 33(3). 290–307. 8 indexed citations
2.
McLaughlin, Peter. (2023). The Coming Hypersonic Era. SHILAP Revista de lepidopterología. 3(2). 47–66. 1 indexed citations
3.
McLaughlin, Peter, et al.. (2019). Biphasic effects of 5-HT1A agonism on impulsive responding are dissociable from effects on anxiety in the variable consecutive number task. Naunyn-Schmiedeberg s Archives of Pharmacology. 392(11). 1455–1464. 7 indexed citations
4.
5.
Thakur, Ganesh A., et al.. (2013). Effects of a novel CB1 agonist on visual attention in male rats: Role of strategy and expectancy in task accuracy.. Experimental and Clinical Psychopharmacology. 21(5). 416–425. 8 indexed citations
6.
Solal‐Céligny, Philippe, Monica Bellei, Luigi Marcheselli, et al.. (2012). Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. Journal of Clinical Oncology. 30(31). 3848–3853. 88 indexed citations
7.
Witzig, Thomas E., Paul A. S. Fishkin, Leo I. Gordon, et al.. (2011). Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leukemia & lymphoma. 52(7). 1188–1199. 25 indexed citations
8.
Wang, Michael, Yasuhiro Oki, Barbara Pro, et al.. (2009). Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 27(31). 5213–5218. 66 indexed citations
9.
Freudenthal, Gideon & Peter McLaughlin. (2009). The social and economic roots of the scientific revolution : texts by Boris Hessen and Henryk Grossmann. Max Planck Institute for Plasma Physics. 6 indexed citations
10.
11.
Rodriguez, Maria Alma, Fernando Cabanillas, Nam H. Dang, et al.. (2004). Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60.. Cancer Research. 64. 507–507. 2 indexed citations
12.
Rodriguez, Maria Alma, Koen van Besien, Fredrick B. Hagemeister, et al.. (2003). Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas. Blood. 102(11). 40216. 2 indexed citations
13.
Esmaeli, Bita, James L. Murray, Moloud Ahmadi, et al.. (2002). Immunotherapy for Low-Grade Non-Hodgkin Secondary Lymphoma of the Orbit. Archives of Ophthalmology. 120(9). 1225–1225. 30 indexed citations
14.
Sarris, A H, K. O. Kliche, A. Preti, et al.. (1999). Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Annals of Oncology. 10(4). 433–440. 132 indexed citations
15.
McLaughlin, Peter. (1999). Immanuel Kant, Kritik der reinen Vernunft, edited by Jens Timmermann, Felix Meiner Verlag Immanuel Kant, Critique of Pure Reason, translated by Werner S. Pluhar with an Introduction by Patricia W. Kitcher, Immanuel Kant, Critique of Pure Reason, tran. Erkenntnis. 51. 14 indexed citations
16.
Berinstein, Neil L., A.J. Grillo-López, Christine A. White, et al.. (1998). Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Annals of Oncology. 9(9). 995–1001. 444 indexed citations
17.
McLaughlin, Peter, A.J. Grillo-López, Brian K. Link, et al.. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.. Journal of Clinical Oncology. 16(8). 2825–2833. 2153 indexed citations breakdown →
18.
McLaughlin, Peter. (1989). Kants Kritik der teleologischen Urteilskraft. Journal of the History of Biology. 23(2). 14 indexed citations
19.
McLaughlin, Peter. (1978). The Thin White Line: Rhodesia's Armed Forces Since the Second World War. Zambezia The Journal of Humanities of the University of Zimbabwe. 6(2). 175–186. 1 indexed citations
20.
McLaughlin, Peter, et al.. (1977). Effect of alfalfa saponins on intestinal cholesterol absorption in rats. American Journal of Clinical Nutrition. 30(12). 2061–2067. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven T. Rosen Breakdown of academic impact, for papers by Shigeo Nakamura Breakdown of academic impact, for papers by Reiner Siebert Breakdown of academic impact, for papers by Peter de Nully Brown Breakdown of academic impact, for papers by Peter C. Nowell̀ Breakdown of academic impact, for papers by Jennifer R. Brown Breakdown of academic impact, for papers by Albert de la Chapelle Breakdown of academic impact, for papers by Charis Eng Breakdown of academic impact, for papers by Anke van den Berg Breakdown of academic impact, for papers by Neil E. Kay
Rankless by CCL
2026